OXLUMO® is an HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of Primary Hyperoxaluria Type 1 (PH1) to lower the urinary oxalate levels in pediatric and adult patients. PH1 is an ultra-rare progressive genetic disease that can be potentially life-threatening.
Manufacturer # 71336100201
Brand Oxlumo®
Manufacturer Alnylam Pharmaceuticals Inc
Country of Origin Unknown
Application Small Interfering Ribonucleic Acid (siRNA) Treatment
Container Type Single-Dose Vial
Dosage Form Injection
Generic Drug Name Lumasiran
Is_Active_Vendor Y
Is_DSCSA N
Is_Discontinued N
Is_Medical_Device Y
Lot_Tracking_Flag N
NDC Number 71336100201
On_Allocation N
Product Dating McKesson Acceptable Dating: we will ship >= 180 days
Supplier_ID 69350688
Type Subcutaneous
UNSPSC Code 41105515
